Mekinist (trametinib tablets and oral solution – Novartis) — Cigna

Initial criteria

• Patient has recurrent disease; AND
• Patient meets ONE of the following (i or ii): i. The medication is used for low-grade serous carcinoma; OR ii. Patient meets BOTH of the following (a and b): a) Patient has BRAF V600 mutation-positive disease; AND b) The medication will be taken in combination with Tafinlar (dabrafenib capsules or tablets for oral suspension).

Approval duration

1 year